Misoprostol

Community-based misoprostol for the prevention of post-partum haemorrhage: A narrative review of the evidence base, challenges and scale-up

Karen Hobday
Jennifer Hulme
Suzanne Belton
Caroline SE Homer
Ndola Prata
Jennifer Hulme
2017

Achieving Sustainable Development Goal targets for 2030 will requirepersistent investment and creativity in improving access to quality healthservices, including skilled attendance at birth and access to emergencyobstetric care. Community-based misoprostol has been extensivelystudied and recently endorsed by the WHO for the prevention of post-partum haemorrhage. There remains little consolidated information aboutexperience with implementation and scale-up to date. This narrativereview of the literature aimed to identify the political processes leading toWHO endorsement of misoprostol for...

“My job is to get pregnant women to the hospital”: a qualitative study of the role of traditional birth attendants in the distribution of misoprostol to prevent post-partum haemorrhage in two provinces in Mozambique

Ndola Prata
Karen Hobday
Jennifer Hulme
Caroline Homer
Páscoa Zualo Wate
Suzanne Belton
2018

Background: Post-partum haemorrhage is the leading cause of maternal deaths in Mozambique. In 2015, the Mozambican Ministry of Health launched the National Strategy for the Prevention of Post-Partum Haemorrhage at the Community Level. The strategy included the distribution of misoprostol to women in advance at antenatal care and via Traditional Birth Attendants who directly administer the medication. The study explores the role of Traditional Birth Attendants in the misoprostol program and the views of women who used misoprostol to prevent post-partum haemorrhage.

...

Misoprostol for the prevention of postpartum haemorrhage in Mozambique: an analysis of the interface between human rights, maternal health and development

Karen Hobday
Anthony B Zwi
Caroline Homer
Renae Kirkham
Jennifer Hulme
Páscoa Zualo Wate
Ndola Prata
2020
Background

Mozambique has high maternal mortality which is compounded by limited human resources for health, weak access to health services, and poor development indicators. In 2011, the Mozambique Ministry of Health (MoH) approved the distribution of misoprostol for the prevention of post-partum haemorrhage (PPH) at home births where oxytocin is not available. Misoprostol can be administered by a traditional birth attendant or self-administered. The objective of this paper is to examine, through applying a human rights lens, the broader contextual, policy and institutional issues that...

Preventing post-partum haemorrhage at home during COVID-19: what are we waiting for?

Karen Hobday
Ndola Prata
Jennifer Hulme
Caroline SE Homer
2021

Disruptions in health service delivery due to the COVID-19 pandemic have had a devastating effect on maternal, neonatal, and child health (MNCH) with rises in maternal and neonatal deaths expected.1 Post-partum haemorrhage is the leading cause of maternal mortality in low-income countries and is likely to increase because of estimates of, at best, a 10% reduction in MNCH services....

In-country availability of medical abortion medicines: a description of the framework and methodology of the WHO landscape assessments

Ulrika Rehnström Loi
Ndola Prata
Amy Grossman
Natalie Williams
Bela Ganatra
Antonella Lavelanet
2023

Background: Availability of quality-assured medical abortion medicines plays a crucial role in providing comprehensive abortion care. However, access to these medicines is still restricted for many abortion seekers. Increasing availability of affordable, quality-assured mifepristone and misoprostol is important to improve access to safe medical abortion services. Driven by the outcomes of a global consultation hosted by the World Health Organization and the Swedish International Development Cooperation Agency in 2018, we decided to holistically examine access to medical...

Landscape assessment of the availability of medical abortion medicines in India.

Priya Karna
Aparna Sharma
Amy Grossman
Madhur Gupta
Tapas Chatterjee
Natalie Williams
Ndola Prata
Annik Sorhaindo
Laurence Läser
Ulrika RehBela Ganatra
Pushpa Chaudhary
Bela Ganatra
2024

Background: Medical abortion with mifepristone and misoprostol can be provided up to 63 days' gestation in India. This accounts for 67.5 percent of all abortions in the country. We conducted an assessment to determine the availability of medical abortion medicines, specifically the combi-pack, in India.

Methods: We applied the World Health Organization landscape assessment protocol at the national level. The assessment protocol included a five-step adaptation of an existing availability framework, including online data collection, desk review,...

A descriptive summary of the WHO availability assessments of medical abortion medicines in eight African countries

Amy Grossman
Ndola Prata
Sarah Jones
Laurence Läser
Bela Ganatra
Antonella Lavelanet
Natalie Williams
Chilanga Asmani
Hayfa Elamin
Leopold Ouedraogo
Lucy Sejo Maribe
Dina Vladimirovna Gbenou
Yelmali Clotaire Hien
Moussa Dadjoari
Fousséni Dao
Mariette Claudia Adame Gbanzi
Robert Mulunda Kanke
Franck Biayi Kanumpepa
Dudu Dlamini
Grace Motsoanku Mefane
Sirak Hailu Bantiewalu
Mary Nana Ama Brantuo
Olive Sentumbwe-Mugisa
Richard Mugahi
Olumuyiwa Adesanya Ojo
Adeniyi Kolade Aderoba
Ulrika Rehnström Loi
2024

Background: The use of medical abortion using either a combination of mifepristone and misoprostol, or misoprostol alone has contributed to increased safety and decreased mortality and morbidity. The availability of quality medical abortion medicines is an essential component in the provision of quality abortion care. Understanding the factors that influence the availability of medical abortion medicines is important to help in-country policymakers, program planners, and providers improve availability and use of medical abortion.

Methods: Using a...